SCHEMBL31380997

SCHEMBL31380997

Oc1ccc(-c2ccn3ccnc3c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 1/20 0.49
DYRK1A Q13627 2/20 0.42
ESR1 P03372 6/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALOX5 P09917 1/20 0.39
ESR2 Q92731 5/20 0.39
ABL1 P00519 4/20 0.39
PIK3CD O00329 2/20 0.39
EGFR P00533 2/20 0.39
HCK P08631 2/20 0.39
SRC P12931 2/20 0.39
PIK3CA P42336 2/20 0.39
PIK3CB P42338 2/20 0.39
MTOR P42345 2/20 0.39
PIK3CG P48736 2/20 0.39
EPHB4 P54760 2/20 0.39
PRKDC P78527 2/20 0.39
QPCT Q16769 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14826051 0.91 PIK3C3 (0.51) PIK3C3DYRK1AMEN1KMT2AABL1
SCHEMBL30186393 0.83 HSD17B2 (0.47) PIK3C3ESR1ESR2PIK3CAHSD17B1
SCHEMBL3321465 0.82 FLT3 (0.48) PIK3C3DYRK1AABL1PIK3CDEGFR
SCHEMBL21364619 0.82 PIK3C3 (0.46) PIK3C3DYRK1AALOX5ABL1PIK3CD
SCHEMBL5252715 0.81 KDR (0.50) PIK3C3DYRK1AMEN1KMT2AABL1
SCHEMBL3196029 0.81 DYRK1A (0.58) PIK3C3DYRK1AABL1PIK3CDEGFR
SCHEMBL5248144 0.79 PIK3C3 (0.47) PIK3C3DYRK1AMEN1KMT2AABL1
SCHEMBL601353 0.79 PIK3C3 (0.41) PIK3C3DYRK1AMEN1KMT2AABL1
SCHEMBL29303281 0.78 PIK3CD (0.44) PIK3C3DYRK1AABL1PIK3CDEGFR
Hydrochloric Acid SCHEMBL26967225 0.77 PIK3C3 (0.40) PIK3C3DYRK1AMEN1KMT2AABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070905-A1 Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity UNIV DE VELENCIA (ES) 2026-03-12 US claimed
WO-2025003545-A1 DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE WITH ANTI-INFLAMMATORY ACTIVITY UNIVERSITAT DE VALÈNCIA (ES) 2025-01-02 WO claimed
US-20260070905-A1 Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity UNIV DE VELENCIA (ES) 2026-03-12 US disclosed
WO-2025003545-A1 DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE WITH ANTI-INFLAMMATORY ACTIVITY UNIVERSITAT DE VALÈNCIA (ES) 2025-01-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070905-A1 Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity IL1A, IL6, IL1B PIK3C3 3057/4885DYRK1A 4627/4885ESR1 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.